Computer-aided detection (CAD) software developer iCAD is highlighting research published on 8 September in Radiology that attests to the ability of its ProFound AI Risk clinical decision-support software to provide accurate two-year breast cancer risk estimates.
The technology is based on data from a woman's 2D digital screening mammogram and is designed to help detect cancers in between screening intervals, the company said. It was developed in collaboration between iCAD and the Karolinska Institute in Stockholm, Sweden, and it includes factors such as a woman's age and breast density to estimate her breast cancer risk.
Karolinska researchers conducted a study that included 974 women with incident cancers and 9,376 healthy women. ProFound AI Risk's area under the receiver operating curve measure was 0.73, which shows high accuracy for risk assessment, according to iCAD. The algorithm also outperformed other models such as the Tyrer-Cusick and the Gail, the company said.
ProFound AI Risk is part of iCAD's Breast Health Solutions suite of products, which also includes ProFound AI for digital breast tomosynthesis, ProFound AI for 2D mammography. iCAD launched ProFound AI Risk in July at the virtual European Congress of Radiology.
